Cypress halts trial for sleep apnea therapy

Cypress Bioscience has pulled the plug on its development program for a combination therapy including mirtazapine for sleep apnea. Phase IIa results don't warrant further investigation, researchers say. Cypress and Organon--a division of Akzo Nobel--each conducted independent studies and are now looking at alternatives to continue their collaboration.

- here's the report on Cypress from StreetInsider.com